Upturn unsubscribed user
$1.14/ day, billed weekly
Cancel anytime
(Ad-Free, Unlimited access)​
NO CREDIT CARD REQUIRED
XBIO logo XBIO
Upturn stock ratingUpturn stock rating
XBIO logo

Xenetic Biosciences Inc (XBIO)

Upturn stock ratingUpturn stock rating
$2.92
Last Close (24-hour delay)
upturn advisory
PASS
  • BUY Advisory
  • SELL Advisory (Profit)​
  • SELL Advisory (Loss)​
  • Profit
  • Loss
  • Pass (Skip investing)
Upturn Stock infoUpturn Stock info Stock price based on last close
*as per simulation
(see disclosures)
Time period over
  • ALL
  • YEAR
  • MONTH
  • WEEK

Upturn Advisory Summary

08/14/2025: XBIO (1-star) is currently NOT-A-BUY. Pass it for now.

Upturn Star Rating

rating

Not Recommended Performance

These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.

Number of Analysts

rating

1 Analysts rated it

Very few follow this stock; limited insights, higher-risk early investing.

1 Year Target Price $40

1 Year Target Price $40

Analysts Price Target For last 52 week
$40 Target price
52w Low $2.2
Current$2.92
52w High $5.27

Analysis of Past Performance

Type Stock
Historic Profit -55.57%
Avg. Invested days 38
Today’s Advisory PASS
Upturn Star Rating Upturn stock ratingUpturn stock rating
Upturn Advisory Performance Upturn Advisory Performance 1.0
Stock Returns Performance Upturn Returns Performance 1.0
Upturn Profits based on simulationUpturn Profits based on simulation Profits based on simulation
Upturn Profits based on simulationUpturn Profits based on simulation Last Close 08/14/2025

Key Highlights

Company Size Small-Cap Stock
Market Capitalization 4.41M USD
Price to earnings Ratio -
1Y Target Price 40
Price to earnings Ratio -
1Y Target Price 40
Volume (30-day avg) 1
Beta 2.33
52 Weeks Range 2.20 - 5.27
Updated Date 08/15/2025
52 Weeks Range 2.20 - 5.27
Updated Date 08/15/2025
Dividends yield (FY) -
Basic EPS (TTM) -2

Analyzing Revenue: Products, Geography and Growth

Revenue by Products

Earnings Date

Report Date -
When -
Estimate -
Actual -

Profitability

Profit Margin -126.03%
Operating Margin (TTM) -122.8%

Management Effectiveness

Return on Assets (TTM) -28.37%
Return on Equity (TTM) -51.83%

Valuation

Trailing PE -
Forward PE -
Enterprise Value -367525
Price to Sales(TTM) 1.8
Enterprise Value -367525
Price to Sales(TTM) 1.8
Enterprise Value to Revenue 0.19
Enterprise Value to EBITDA 1.03
Shares Outstanding 1542140
Shares Floating 1182805
Shares Outstanding 1542140
Shares Floating 1182805
Percent Insiders 19.05
Percent Institutions 4.8

ai summary icon Upturn AI SWOT

Xenetic Biosciences Inc

stock logo

Company Overview

overview logo History and Background

Xenetic Biosciences, Inc. is a biopharmaceutical company focused on developing innovative therapeutics. Founded in 2003, it has focused on polymer-based drug delivery and has gone through multiple strategic shifts. Key milestones include development programs utilizing PolyXen technology.

business area logo Core Business Areas

  • Oncology: Focused on developing therapies for cancer, particularly targeting solid tumors. This segment utilizes Xenetic's PolyXen technology.
  • COVID-19 vaccine: Developing novel vaccine therapies for infectious diseases, including a potential COVID-19 vaccine.

leadership logo Leadership and Structure

The leadership team includes a Chief Executive Officer (CEO) and a board of directors. The organizational structure typically includes departments for research and development, clinical trials, regulatory affairs, and finance.

Top Products and Market Share

overview logo Key Offerings

  • ErepoXen: ErepoXen, a long-acting form of erythropoietin (EPO) for treating anemia. Competitors: Amgen (AMGN) with Epogen/Aranesp, Johnson & Johnson (JNJ) with Procrit/Eprex. Market share data is not publicly available.
  • OncoHist: OncoHist, a potential treatment for cancer. Market share data is not publicly available at the development stage. Competitors depend on the specific cancer target if approved.

Market Dynamics

industry overview logo Industry Overview

The biopharmaceutical industry is characterized by high research and development costs, lengthy regulatory approval processes, and significant competition. Innovation and patent protection are crucial for success.

Positioning

Xenetic is a smaller player in the biopharmaceutical industry, focusing on niche therapeutic areas. Its competitive advantage lies in its PolyXen technology, which aims to improve drug delivery and efficacy.

Total Addressable Market (TAM)

The total addressable market (TAM) for oncology therapeutics is estimated to be in the hundreds of billions of dollars globally. Xenetic Biosciences, Inc. is attempting to penetrate a very small section of this market with novel treatments.

Upturn SWOT Analysis

Strengths

  • Proprietary PolyXen technology
  • Potential for improved drug delivery
  • Pipeline of therapeutic candidates

Weaknesses

  • Limited financial resources
  • Small market capitalization
  • Dependence on clinical trial success

Opportunities

  • Partnerships with larger pharmaceutical companies
  • Successful clinical trial outcomes
  • Expanding applications of PolyXen technology

Threats

  • Regulatory hurdles
  • Competition from established players
  • Failure of clinical trials

Competitors and Market Share

competitor logo Key Competitors

  • AMGN
  • JNJ
  • VTRS

Competitive Landscape

Xenetic faces significant competition from larger, more established pharmaceutical companies with greater resources and broader product portfolios. Its PolyXen technology offers a potential competitive edge if proven effective.

Growth Trajectory and Initiatives

Historical Growth: Historical growth has been limited due to the company's development stage and lack of product revenue.

Future Projections: Future projections are speculative and depend on the success of clinical trials and regulatory approvals. Analyst estimates vary widely.

Recent Initiatives: Recent initiatives likely include progressing clinical trials for its lead therapeutic candidates and securing funding for operations.

Summary

Xenetic Biosciences is a development-stage biopharmaceutical company with limited revenue and high risk. Its PolyXen technology offers potential, but the company depends on clinical trial success and funding. It faces significant competition and regulatory hurdles. Success depends on the ability to advance its pipeline and secure partnerships.

Peer Comparison

Sources and Disclaimers

Data Sources:

  • Company website
  • SEC filings
  • Industry reports
  • Analyst reports (where available)

Disclaimers:

This analysis is based on publicly available information and represents an opinion. It is not financial advice. Investors should conduct their own due diligence before making any investment decisions. Market share estimations are approximate.

Upturn AI SummarizationUpturn AI Summarization AI Summarization is directionally correct and might not be accurate.

Upturn AI SummarizationUpturn AI Summarization Summarized information shown could be a few years old and not current.

Upturn AI SummarizationUpturn AI Summarization Fundamental Rating based on AI could be based on old data.

Upturn AI SummarizationUpturn AI Summarization AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.

About Xenetic Biosciences Inc

Exchange NASDAQ
Headquaters Framingham, MA, United States
IPO Launch date 2014-06-30
CFO, COO, Interim CEO & Corporate Secretary Mr. James F. Parslow
Sector Healthcare
Industry Biotechnology
Full time employees 2
Full time employees 2

Xenetic Biosciences, Inc., a biopharmaceutical company, focuses on advancing immune-oncology technologies to treat cancers. The company's proprietary DNase platform is designed to improve outcomes of existing treatments, including immunotherapies, by targeting neutrophil extracellular traps (NETs), which are involved in cancer progression, pancreatic ductal adenocarcinoma, colorectal carcinoma, and other gastrointestinal cancer. Its product pipeline includes XBIO-015 for treating pancreatic carcinoma and solid tumors; and XBIO-020 for treating solid tumors. The company also has partnered with biotechnology and pharmaceutical companies to develop its proprietary drug delivery platform, PolyXen, which as an enabling platform technology for protein and peptide drug delivery. It has collaboration agreements with Belgian Volition SARL Limited to develop NETs-targeted adoptive cell therapies for the treatment of cancer, as well as PJSC Pharmsynthez and Serum Institute of India to develop and launch ErepoXen for the treatment of anemia in chronic kidney disease patients; sublicensing agreement with Takeda Pharmaceutical Co. Ltd; exclusive sublicense agreement with CLS Therapeutics Ltd to develop DNase technology for the treatment of immunotherapies. The company offers under XDNASE, XCART, OncoHist, PolyXen, ErepoXen, and ImuXen trandemarks. Xenetic Biosciences, Inc. is headquartered in Framingham, Massachusetts.